Integral Intestinal Transit Management System for chronic constipation

Projektinformationen

MOWOOT

ID Finanzhilfevereinbarung: 756280

DOI 10.3030/756280

Abgeschlossenes Projekt

EK-Unterschriftsdatum 23 Mai 2017

Startdatum 1 April 2017

Enddatum 30 November 2019

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 1 632 148,75

EU-Beitrag € 1 142 504,13

Koordiniert durch

USMIMA SL
Spain

Ziel

Up to 15% of the EU and USA population suffer from Chronic Constipation. The most affected collectives are women, aging people and patients with Neurogenic Bowel disorders related to Spinal cord injury, Parkinson and Multiple Sclerosis. Constipation causes a painful evacuation, faecal impaction and faecal incontinence, which have a big negative impact on the quality of life of these patients.

USMIMA S.L. created in 2014, offers MOWOOT, a non-pharmacological, non-invasive solution to relieve chronical constipation, without side-effects, in form of a wearable class II medical device that automatically emulates the abdominal massage techniques of professional therapists via a number of actuators. A pilot study with chronically constipated patients has already shown that the daily use of MOWOOT ameliorates idiopathic chronic constipation (TRL7).


USMIMA wants to target a 90B M€ market of 150 million people with chronic constipation identified. A feasibility study showed that, in order to target this market and increase the influence on target clients, USMIMA has to priorize the following activities during this phase 2:

• Conduct a larger clinical study as a marketing strategy to build confidence in the medical sector and promote MOWOOT prescriptions
• Upgrade Mowoot 1.0 prototype to Mowoot 2.0 product, by adding cloud and smart services and other features required by users
• Reduce costs (below current 500€) through scaling the manufacturing process

MOWOOT is expected to produce a big impact on USMIMA by:
• Generating 2.5 M€ of EBITDA by 2018
• Incorporating 5 new specialized employees to complement current staff profiles
• Introducing MOWOOT products in EU and USA markets by 2019

Moreover, MOWOOT will empower patients and elderly people, enhance well-being among the society, increase autonomy and reduce the increasing health care expenses due to aging population and the derived long-term cares.

Wissenschaftliches Gebiet

• engineering and technology › mechanical engineering › manufacturing engineering
• natural sciences › computer and information sciences › internet › internet of things
• natural sciences › computer and information sciences › software › software development
• medical and health sciences › basic medicine › neurology › multiple sclerosis
• medical and health sciences › basic medicine › neurology › parkinson

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.4. - Active ageing and self-management of health
• H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
• H2020-EU.3.1.6. - Health care provision and integrated care

Thema/Themen

• SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-2-2016-2017

Finanzierungsplan

SME-2 - SME instrument phase 2

Koordinator

USMIMA SL

• Netto-EU-Beitrag: € 1 142 504,13
• Adresse: AVDA. NURIA 22 URB. MAS DE CAN PI DE CERVELLO ; 08758 CERVELLO BARCELONA ; Spanien
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Este › Cataluña › Barcelona
• Region: Este › Cataluña › Barcelona
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 1 632 148,75